Is there a diabetes pill that works better than oral semaglutide?
Yes. In this 52-week phase 3 trial, the once-daily pill orforglipron lowered blood sugar and body weight more than oral semaglutide in adults with type 2 diabetes. At the top dose, it cut HbA1c by about 2.2% and body weight by about 9.2%, compared to about 1.4% and 5.3% for semaglutide.
For years, the strongest GLP-1 drugs came as weekly shots. Oral semaglutide changed that by putting a GLP-1 medicine into a daily tablet, but it has to be taken on an empty stomach with strict timing rules. This new trial, called ACHIEVE-3, tested whether a different kind of pill could do the same job with fewer rules and better results.
How the new pill works
Orforglipron is a small-molecule GLP-1 receptor agonist. In plain terms, it copies a natural gut hormone that tells your body you are full and helps control blood sugar after meals. GLP-1 drugs like semaglutide do the same thing, but they are large, protein-based molecules that your gut breaks down easily. That is why most need injections, and why oral semaglutide needs careful timing on an empty stomach.
Because orforglipron is a small chemical rather than a protein, it survives digestion better. In this study, people took it once a day with no food or water restrictions. That is a real practical difference, since the timing rules for oral semaglutide can be hard to follow every single day.
What the data show
The trial enrolled 1,698 adults with type 2 diabetes whose blood sugar was not well controlled on metformin alone. Over 52 weeks, orforglipron beat oral semaglutide on the two measures that matter most in diabetes care. At the top dose, it lowered HbA1c, a marker of average blood sugar over three months, by roughly 2.2%, compared to about 1.4% for semaglutide. It also cut body weight by about 9.2%, versus about 5.3% for the semaglutide group.
The benefits went beyond sugar and weight. Orforglipron also improved blood pressure and cholesterol markers, both of which raise heart risk in people with diabetes. The main downside was gastrointestinal side effects, mostly nausea. These were more common with orforglipron than with semaglutide, but they were generally mild to moderate and clustered during the early weeks when the dose was being raised.
Dr. Kumar’s Take
What stands out to me is that this pill did not just match oral semaglutide, it clearly beat it on blood sugar and weight while dropping the annoying food and timing rules. For a patient, “take it whenever, with or without food” is a big deal, because the medicine only works if people actually take it consistently. The bonus improvements in blood pressure and cholesterol are encouraging too, since diabetes is really a whole-body cardiovascular problem, not just a sugar problem.
I do want to keep this in perspective. This was an open-label trial, meaning both patients and doctors knew which drug was being used, and that can nudge results. Fifty-two weeks is a solid look but not a long-term one, and we do not yet have hard outcomes like heart attacks or strokes prevented. The nausea is also real, so how the dose is raised will matter in practice.
Study snapshot
ACHIEVE-3 was a multinational, multicenter, phase 3 trial designed to test non-inferiority, meaning the first goal was simply to show orforglipron was not worse than oral semaglutide. It went further and showed the pill was actually better on the main measures. Participants were adults with type 2 diabetes still above target on metformin, a very common real-world starting point. The head-to-head design is what makes this useful, because it compares the new pill against the best oral option we already have, not against a placebo.
Who benefits most
The people most likely to gain here are those who need better blood sugar control and meaningful weight loss but want to avoid injections. The freedom from food and water timing also helps anyone who has struggled to follow the strict rules that come with oral semaglutide. People who are especially sensitive to nausea may need a slower dose increase to stay comfortable during the first weeks.
Practical Takeaways
- If you take metformin but your blood sugar is still high, ask your doctor whether a GLP-1 pill could be a next step for you.
- Expect nausea to be most likely in the first few weeks as the dose goes up, and ask about a slower increase if side effects bother you.
- Do not stop or switch any diabetes medicine on your own, since these drugs were studied under medical supervision and dosing matters.
- Track weight, blood pressure, and cholesterol along with blood sugar, since this class of drug can improve all of them.
Related Studies and Research
- A weekly shot for type 2 diabetes that also drops 14% of body weight
- New pill cuts LDL cholesterol by 57% in major trial
- Creatine for type 2 diabetes: a placebo-controlled trial
- A randomized controlled trial of mindfulness-based cognitive therapy for major depressive disorder in undergraduate students
FAQs
Is orforglipron the same thing as Ozempic or Wegovy?
No. Ozempic and Wegovy are brand names for semaglutide, which is a large protein-based drug usually given as a weekly injection. Orforglipron is a different, smaller chemical that works on the same GLP-1 receptor but can be made into a daily pill that survives digestion. That difference is what lets people take orforglipron without the strict empty-stomach rules that oral semaglutide requires.
How much weight did people lose on the new pill?
At the highest dose, people taking orforglipron lost about 9.2% of their body weight over 52 weeks, compared to about 5.3% for those on oral semaglutide. For someone weighing 200 pounds, that top-dose figure works out to roughly 18 pounds. Keep in mind this was measured in people with type 2 diabetes on metformin, and individual results always vary with diet, activity, and dose.
What are the main side effects to expect?
The most common problems were gastrointestinal, mainly nausea, and they showed up most often while the dose was being raised. In this trial these effects were generally mild to moderate rather than severe. Raising the dose slowly usually helps the stomach adjust, and side effects tend to ease over time. Anyone who has ongoing or severe symptoms should talk with their doctor about adjusting the plan.
Bottom Line
In a head-to-head phase 3 trial of nearly 1,700 adults with type 2 diabetes, the once-daily pill orforglipron beat oral semaglutide on the measures that matter most, lowering HbA1c by about 2.2% and body weight by about 9.2%, along with better blood pressure and cholesterol. It did this without the strict food and timing rules of oral semaglutide, at the cost of more early nausea. If longer trials confirm these gains and show real heart benefits, this could become a leading oral option for type 2 diabetes.
